Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ASP Isotopes Inc. Common Stock(ASPI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ASPI
09/25/2026: ASPI (1-star) is currently NOT-A-BUY. Pass it for now.
ASP Isotopes is a pre-commercial firm focused on using its proprietary Aerodynamic Separation Process to enrich isotopes for the medical and quantum computing industries. The company's primary strength lies in this potentially more efficient enrichment technology, which aims to challenge established supply chains. The core investment story centers on the transition from R&D to commercial-scale isotope production, specifically for pharmaceutical applications. However, the company faces high execution risks, regulatory hurdles, and substantial financial requirements as it scales. It is most suitable for growth-oriented investors with a high risk tolerance, who should monitor milestones like facility licensing and the announcement of commercial supply agreements.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential high growth via disruptive technology but remains pre-revenue and speculative. |
| Momentum investor | Mixed fit | Momentum may be driven by news of successful facility commissioning or major customer contracts, but volatility is extremely high. |
| Value investor | Weak fit | As an early-stage company with no consistent earnings, it does not meet standard value investment criteria. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into R&D and facility construction. |
| Low-risk investor | Weak fit | The high execution and financial risk profile make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to speculative news and small-cap market dynamics. |
| Valuation risk | High | Valuation is based on future potential rather than current cash flow, creating significant downside risk if targets are missed. |
| Competition risk (Nuclear Technology) | Medium / high | Established players have entrenched supply chains that are difficult for new entrants to disrupt. |
| Business quality | Medium | The business model depends entirely on the commercial success of unproven, novel technology. |
| Dividend income | Low / none | There is no dividend income and none is expected in the near term. |
| Execution risk | High | Scaling technology from a laboratory setting to commercial production is prone to significant delays and cost overruns. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 43.31% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 452.26M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 3.8M shares | Beta 3.6 | 52 Weeks Range 2.88 - 14.49 | Updated Date 09/24/2026 |
52 Weeks Range 2.88 - 14.49 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.41 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Isotope Sales | Sale of enriched isotopes like C-14 and Si-28 to pharmaceutical and tech customers. | The company plans to generate revenue by becoming a primary supplier of specialized materials for medicine and computing. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 54.35 | Enterprise Value 476.88M | Price to Sales(TTM) 14.66 |
Enterprise Value 476.88M | Price to Sales(TTM) 14.66 | ||
Enterprise Value to Revenue 15.46 | Enterprise Value to EBITDA -12.17 | Shares Outstanding 153.31M | Shares Floating 133.03M |
Shares Outstanding 153.31M | Shares Floating 133.03M | ||
Percent Insiders 10.5 | Percent Institutions 48.11 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About ASP Isotopes Inc. Common Stock
Exchange NASDAQ | Headquarters Dallas, TX, United States | ||
IPO Launch date 2022-11-10 | Executive Chairman & CEO Mr. Paul Elliot Mann C.F.A. | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 271 | Website https://aspisotopes.com |
Full time employees 271 | Website https://aspisotopes.com | ||
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.